Journal article
Impact of Candesartan on Nonfatal Myocardial Infarction and Cardiovascular Death in Patients With Heart Failure
Abstract
CONTEXT: Angiotensin-converting enzyme (ACE) inhibitors reduce the risk of myocardial infarction (MI), but it is not known whether angiotensin receptor blockers have the same effect.
OBJECTIVE: To assess the impact of the angiotensin receptor blocker candesartan on MI and other coronary events in patients with heart failure.
Authors
Demers C; McMurray JJV; Swedberg K; Pfeffer MA; Granger CB; Olofsson B; McKelvie RS; Östergren J; Michelson EL; Johansson PA
Journal
JAMA: The Journal of the American Medical Association, Vol. 294, No. 14, pp. 1794–1798
Publisher
American Medical Association (AMA)
Publication Date
October 12, 2005
DOI
10.1001/jama.294.14.1794
ISSN
0098-7484
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AgedAngina, UnstableAngiotensin II Type 1 Receptor BlockersBenzimidazolesBiphenyl CompoundsFemaleFollow-Up StudiesHeart FailureHospitalizationHumansMaleMiddle AgedMyocardial InfarctionMyocardial RevascularizationProportional Hazards ModelsRandomized Controlled Trials as TopicSurvival AnalysisTetrazolesTreatment Outcome